α-干扰素联合羟基脲治疗慢性粒细胞白血病的疗效观察  

INTERFERON COMBINED WITH HYDROXYUREA TREATMENT OF CHRONIC MYELOID LEUKEMIA

作　　者：苏力[1] 田丁[1] 徐娟[1] 李亚林[1] 荆华[1] 崔小华[1] 孙雪静[1] 

机构地区：[1]首都医科大学宣武医院

出　　处：《白血病》1999年第3期147-149,共3页

摘　　要：目的探讨ＩＮＦ－α联合羟基脲（ＨＵ）治疗慢性粒细胞白血病的效果。方法对１２例Ｐｈ１阳性和ｂｃｒ／ａｂｌ基因阳性的ＣＭＬ患者进行治疗并定期观察治疗前后血象、骨髓象、染色体和ｂｃｒ／ａｂｌ基因的变化。结果全部病例均达血液学缓解，其中１例达细胞遗传学部分缓解，另１例患者不仅达细胞遗传学完全缓解，而且在治疗１６个月后ｂｃｒ／ａｂｌ基因消失。结论ＩＮＦ－α联合ＨＵ是治疗ＣＭＬ的有效方法，而且能达到分子生物学缓解的效果，早期治疗，ＩＮＦ－α剂量充足和持续的治疗是达到ＣＭＬ长期彻底缓解的重要因素。Objective Interferonalpha (INF)is considered as the standard therapy for chronic myeloid leukemia patients who are in chronic phase.It is reported this therapy can achieve completed hematologic response(CHR) and cytogenetic response.But the effect of INF on bcr/abl gene was rarely reported. Methods 12 CML patients treated with INF combining with hydroxyurea(HU) were evaluated. All patients were Ph1 and bcr/abl positive before treatment.The median following up was 19 months (range 4 to 53 months). Results The CHR rate was 100%.One of the twelve patients achieved minor cytogenetic response(MCR) and the other one had completed cytogenetic response(CCR). The patients who had CCR after 8 months INF2b combining HU achieved bcr/abl disappearance (investigated by reverse) transcription polymerase chain reaction (RTPCR) 8 months late and keep on bcr/abl negative from then on. Conclusion The result of the disappearance of bcr/abl was attributed to the early diagnosis and timely treatment.

关 键 词：Α干扰素 慢性 白血病 羟基脲 治疗 

分 类 号：R733.720.5[医药卫生—肿瘤]